Contact Us
Drug Search Results
More Filters [+]

Padeliporfin

Alternative Names: padeliporfin, wst-11, wst11, wst 11
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation:
Fast Track - Transitional Cell Carcinoma
Orphan Drug - Pancreatic Cancer
Orphan Drug - Transitional Cell Carcinoma *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Mexico | Poland | Portugal | Slovakia | Sweden

Approved Indications: None

Known Adverse Events: None

Company: Steba Biotech
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Padeliporfin

Countries in Clinic: Austria, France, Germany, Israel, Italy, Spain, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Bladder Cancer|Kidney Cancer|Kidney Diseases|Transitional Cell Carcinoma|Ureteral Cancer|Vascular Cancer

Phase 2: Prostate Cancer

Phase 1: Adenocarcinoma|Deglutition Disorders|Gastrointestinal Cancer|Lung Cancer|Nose Cancer|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CLIN2001UCM301

P3

Unknown Status

Transitional Cell Carcinoma

2028-08-01

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

P3

Active, not recruiting

Transitional Cell Carcinoma

2028-05-11

CLIN2201 LCM101

P1

Recruiting

Nose Cancer|Vascular Cancer|Lung Cancer

2027-05-30

CLIN2301 PNCM101

P1

Recruiting

Pancreatic Cancer|Adenocarcinoma

2026-05-30

Recent News Events

Date

Type

Title

12/04/2024

News Article

 ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2024

11/07/2024

News Article

 ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024

10/25/2024

News Article

 ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024

09/27/2024

News Article

 ImPact Biotech Announces 50% Enrollment in Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP in Low Grade Upper Tract Urothelial Cancer

09/30/2023

PubMed

 Advances in chemoablation in upper tract urothelial carcinoma: overview of indications and treatment patterns.

05/01/2023

PubMed

 Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.

10/04/2022

PubMed

 Emerging photodynamic/sonodynamic therapies for urological cancers: progress and challenges.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions